The continuous activation of Nrf2 in lung cancer cells is generally due to the mutation of the Keap1/NFE2L2 gene, thus resulting in drug resistance and significant invasiveness (Zhang et al., 2019). Here, KEAP1 is linked to lung carcinoma.